Enveric Biosciences, Inc.: Form 10-Q for the period ended Jun 30, 2022
Filed with the SEC on Aug 12, 2022 and accepted by EDGAR at Aug 12, 2022, 16:23 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2022-04-01 to 2022-06-30 | $2.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2022-01-01 to 2022-06-30 | $4.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2022-04-01 to 2022-06-30 | −$4.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2022-01-01 to 2022-06-30 | −$9.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-04-01 to 2022-06-30 | $668 | us-gaap:InterestExpense |
| Interest expense | 6 months2022-01-01 to 2022-06-30 | $4.8k | us-gaap:InterestExpense |
| Net income | 3 months2022-04-01 to 2022-06-30 | −$2.8m | us-gaap:NetIncomeLoss |
| Net income | 6 months2022-01-01 to 2022-06-30 | −$7.3m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2022-04-01 to 2022-06-30 | −$2.73 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2022-01-01 to 2022-06-30 | −$7.78 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 6 months2022-01-01 to 2022-06-30 | −$9.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2022-01-01 to 2022-06-30 | $559.4k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-06-30 | $18.0m | us-gaap:Cash |
| Current assets | At period end2022-06-30 | $19.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-06-30 | $28.6m | us-gaap:Assets |
| Current liabilities | At period end2022-06-30 | $2.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-06-30 | $6.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-06-30 | $22.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-22-022369. Last ingested by Listed: Nov 14, 2026, 20:02 ET. Listed shows no prices and gives no investment advice.